Qlarity Imaging CEO Jon DeVries Named an AI Activator by The Imaging Wire

Top Quote DeVries honored for advancements to the diagnostic AI technology QuantX that improves radiologist performance in characterizing breast abnormalities in MRI exams. End Quote
  • Chicago, IL (1888PressRelease) December 18, 2020 - Jon DeVries, the chief executive officer of Qlarity Imaging—a leading innovator in artificial intelligence (AI) diagnostics—has been recognized as an AI Activator by The Imaging Wire. Under Mr. DeVries’ leadership, Qlarity Imaging has made significant progress in advancing QuantX, the first diagnostic AI software to be cleared by the U.S. Food and Drug Administration, to help radiologists distinguish between benign and malignant breast lesions during MRI exams.

    “Intuitive workflows and accessibility are critical for applying AI solutions to improve patient care,” said Mr. DeVries. “Joining Qlarity Imaging in January, I built upon QuantX’s award-winning technology through product advancements and industry partnerships that bring the value of AI to more radiologists, ultimately helping more patients in need.”

    The Imaging Wire Awards honor the year’s most outstanding contributors to radiology and their efforts in evolving the discipline. A panel of judges selected Mr. DeVries for his innovative approach to product development and collaborations that have expanded the capabilities and market reach of QuantX for the benefit of radiologists and their patients.

    Mr. DeVries is leading the Qlarity team in transforming the current QuantX workstation into a cloud-based diagnostic AI service that can overlay customers’ existing picture archive and communication systems (PACS).* The new release incorporates customer feedback and industry trends to provide greater transparency and intuitive workflows. He also spearheaded a collaboration with Ikonopedia to create a unified diagnostic and reporting application for radiologists. The integrated solution helps deliver more accurate data-driven diagnosis, simplify the reporting workflow by eliminating the need to type or dictate information, and reduce dictation or data entry errors.

    “Making meaningful contributions to the health care systems that society relies on requires investing in revolutionary technology and demands visionary leaders, like Jon, who inspire change and activate innovation,” said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. “By leveraging advancements in AI, Paragon and Qlarity have a profound opportunity to solve key challenges that can change lives and improve the world.”

    Qlarity Imaging and QuantX have received numerous accolades throughout the years, including being named one of TIME’s 100 Best Inventions of 2019, a 2020 Gold Edison Award, recognized as a Top 10 Medical Imaging Solutions Provider of 2020 by Healthcare Tech Outlook and contributing to Paragon’s recognition as one of Fast Company’s 10 Most Innovative Health Companies of 2020.

    To read more about the 2020 Imaging Wire Awards, visit www.theimagingwire.com.

    *This release is a work in progress. Qlarity Imaging cannot guarantee if or when it will be released or if it will receive the necessary regulatory clearances.

    Indication: QuantX is indicated for the assessment and characterization of breast abnormalities from MRI data in patients presenting for high-risk screening, diagnostic imaging workup, or evaluation of extent of known disease. QuantX is not intended for primary interpretation of digital mammography images.

    Risk Information: QuantX is not intended for primary interpretation of digital mammography images. Labeling also provides information to users about potential limitations of the device related to specific subpopulations. For use by licensed healthcare professionals only.

    About Qlarity Imaging
    Qlarity Imaging assists radiologists in diagnosing breast abnormalities with AI-driven technology that enhances clinical insights. Using quantitative analysis to improve decision making, we provide value to radiologists, health systems, and most importantly patients. Qlarity’s award-winning initial product, QuantX, is the first computer-aided diagnosis software to be cleared by the FDA for breast MRI evaluation. Qlarity Imaging was founded by Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology, and biopharmaceuticals. For more information, please visit www.qlarityimaging.com.

    About Paragon Biosciences
    Qlarity Imaging is a portfolio company of Paragon Biosciences. Paragon is a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by our replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com.

    About The Imaging Wire
    The Imaging Wire is a newsletter and website dedicated to making it easy for the people of medical imaging to be well informed about their specialty and industry. Read twice weekly by thousands of global radiology professionals, The Imaging Wire is the first publication from business news company, Insight Links, which is dedicated to expanding news literacy across healthcare. For more information: www.theimagingwire.com.

  • FB Icon Twitter Icon In-Icon
Contact Information